StockData
Natera, Inc. logo

Natera, Inc. (NTRA) KPIs and segments

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30138% above fair value
$289.50+2.03 (+0.71%)

Close on Nov 18, 2026Market cap $41.73BP/E –Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Natera · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Natera: 31 chỉ số vận hành, trong đó có Total Tests Processed, Total Consolidated Revenue và U.S. Direct Sales Force Revenue Share, lấy từ 170 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Product revenues($M)
748694661590544500473436411365307265
Licensing and other revenues($M)
4.822.784.341.992.171.793.153.631.993.073.853.09
United States($M)
739686652582538492467426405359301260
Europe, Middle East, India, Africa($M)
9.026.436.015.416.057.725.445.185.26
Americas, excluding U.S.($M)
2.222.404.571.521.571.691.542.001.601.481.261.29
Asia Pacific and Other($M)
2.052.222.132.281.821.781.793.761.441.671.891.89
Product revenues($M)
481449442383345315297268242206156118
Licensing and other revenues($M)
3.862.173.501.441.711.342.693.281.662.763.652.74
Total Tests Processed — Lab + Constellation Platform (tests)3
1,043,900.001,013,600.00923,600.00893,600.00853,100.00855,100.00792,800.00775,800.00760,300.00735,800.00626,800.00626,000.00
Tests Accessioned in Natera's CLIA Laboratories (tests)
1,030,100.00999,200.00909,000.00879,700.00839,300.00840,800.00778,400.00760,700.00744,000.00718,700.00610,100.00609,800.00
Total Tests Reported — Resulting in a Customer Report (tests)1
985,500.00931,600.00892,400.00832,900.00812,900.00804,800.00771,700.00750,100.00725,200.00679,400.00619,800.00590,000.00
Tests Reported in Natera's CLIA Laboratories (tests)
972,000.00918,100.00878,000.00819,900.00799,900.00791,400.00758,200.00735,900.00709,800.00663,500.00604,200.00575,000.00
Total Oncology Tests Processed — Signatera MRD + Altera + Research (tests)2
296,700.00258,900.00233,300.00211,000.00188,800.00167,700.00150,800.00137,100.00125,400.00114,800.0097,500.0088,800.00
Clinical MRD Oncology Tests Processed — Quarterly (thousand tests)
283.00249.00225.00202.00181.00161.00145.00130.00118.00106.0091.0081.00
Signatera Clinical Average Selling Price — Realized ASP ($/test)($)
1,2751,2501,2251,2001,175
Total Consolidated Revenue — Disaggregated by Payer & Product ($M)($M)3
753697666592547502476440413368311268
Insurance Carriers Revenue — Third-Party Commercial & Government Payers ($M)($M)
705658622560517473441405384341277240
Laboratory Partners & Hospitals Revenue — Institutional Payers ($M)($M)
37.728.835.025.122.220.827.127.622.320.326.921.7
Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M)($M)
9.929.748.437.587.448.357.556.936.976.446.726.79
U.S. Direct Sales Force Revenue Share (%)(%)1
96.0%94.0%
U.S. Laboratory Partners Revenue Share (%)(%)
2.0%5.0%
Revenue Recognized from Prior-Period Completed Tests — Cash Collection True-Ups ($M)($M)2
52.36159.755.145.334.343.134.539.933.792.20
Diluted EPS Impact of Prior-Period Revenue True-Ups ($/sh)($)
0.360.430.400.330.250.280.320.280.02
Revenue Offset for Prior-Period Insurance Non-Refunded Considerations ($M) [legacy through Q3 2025]($M)
0.200.403.50-0.200.400.60-1.50
GAAP Gross Profit ($M)($M)1
485451445384347317300272243209160121
GAAP Gross Margin (%)(%)
64.5%64.7%66.9%64.9%63.4%63.1%62.9%61.8%58.8%56.7%51.4%45.1%
Total Contract Liabilities — Deferred Revenue ($M)($M)10
56.653.942.038.238.137.336.634.836.836.535.736.1
Deferred Revenue, Current ($M)($M)
40.636.924.921.821.620.619.817.918.417.716.615.0
Deferred Revenue, Long-Term / Noncurrent ($M)($M)
16.11717.116.416.516.716.816.918.418.819.121.0
Contract Liability Roll-Forward: Additions / Deferrals in Period ($M)($M)
26.428.419.610.510.210.211.59.146.897.9411.07.15
Contract Liability Roll-Forward: Revenue Recognized from Beginning Balance ($M)($M)
-11.8-11.3-2.80-1.50-5.48-9.42-1.59-2.45-2.60-7.05-0.95-2.09
Contract Liability Roll-Forward: Revenue Recognized from Same-Period Deferrals ($M)($M)
-11.8-5.23-13.1-8.79-3.93-0.07-8.09-8.66-4.04-0.10-9.84-6.17
BGI Genomics License Agreement — Current Contract Liability ($M) [legacy through Q3 2025]($M)
0.500.500.500.500.500.501.201.20
BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025]($M)
16.416.516.716.816.918.417.317.619.3
Foundation Medicine Collaboration — Current Contract Liability ($M) [legacy through Q3 2025]($M)
1.701.701.501.70331.601.702.20
Genetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025]($M)
19.619.418.614.414.814.913.712.8
BGI Genomics Remaining Performance Obligations — RPO ($M) [legacy through Q1 2025]($M)
620666
Total Unconditional Purchase Obligations ($M)($M)6
22126125715817716917110110492.494.564.6
Inventory & Laboratory Sequencing Materials Purchase Obligations ($M)($M)
12013610761.580.870.454.034.435.624.620.723.3
Other Material Supplier Purchase Obligations ($M)($M)
48.372.489.139.839.344.651.225.722.316.911.914.7
Application & IT Enterprise Services Purchase Obligations ($M)($M)
15.916.413.67.335.684.734.233.904.194.5112.614.6
Laboratory Sequencing Instruments & Equipment Purchase Obligations ($M)($M)
13.416.218.921.223.521.427.72.244.407.629.409.40
Cloud Computing & Bioinformatics Infrastructure Purchase Obligations ($M)($M)
22.720.228.028.427.427.434.234.236.638.440
Clinical Trial Samples & Registry Study Purchase Obligations ($M)($M)
1.301.301.3066613
Property and Equipment, Gross ($M)($M)8
451390352307281267240213198185168155
Machinery and Laboratory Sequencing Equipment, Gross ($M)($M)
21518317115314012911710494.890.785.683.5
Laboratory & Facility Leasehold Improvements, Gross ($M)($M)
76.862.562.249.249.248.948.648.147.747.53939
Construction in Progress — Lab Expansion & Automation ($M)($M)
13112094.083.773.771.358.546.641.633.229.420.8
Capitalized Internal-Use Software, Gross ($M)($M)1
21.620.121.217.614.914.613.211.110.711.111.610.3
Capitalized Internal-Use Software, Net Carrying Value ($M)($M)
31.23.502.40
Computer & Bioinformatics Hardware Equipment, Gross ($M)($M)
5.383.993.633.443.343.293.183.043.0421.851.81
Less: Accumulated Depreciation and Amortization ($M)($M)
13312011110191.786.678.471.164.558.756.350.6
Property and Equipment, Net ($M)($M)
318269241207189180162142133126111105
Depreciation Expense on Property and Equipment ($M)($M)
13.112.610.19.308.908.207.306.6076.306.605.90
Acquired Finite-Lived Intangible Assets, Gross ($M)($M)3
37937937911.9
Less: Accumulated Amortization of Intangible Assets ($M)($M)
19.212.04.880.96
Acquired Finite-Lived Intangible Assets, Net ($M)($M)
36036737410.9
Foresight Diagnostics Acquisition Contingent Consideration Liability — Total Fair Value ($M)($M)2
121126118
Foresight Contingent Consideration — Current Liability ($M)($M)
22.822.421.6
Foresight Contingent Consideration — Noncurrent Liability ($M)($M)
97.710396.8
Total Operating Lease Liabilities ($M)($M)8
15816013411811611510710973.676.178.779.3
Operating Lease Right-of-Use (ROU) Assets ($M)($M)
13013410997.095.194.686.287.952.654.656.558.2
Operating Lease Liabilities, Current ($M)($M)
15.114.815.614.013.112.210.29.7612.412.011.611.0
Operating Lease Liabilities, Noncurrent ($M)($M)
14314511810410310396.699.061.264.267.068.3
Operating Lease Cost ($M)($M)
7.425.935.455.404.964.394.153.973.613.593.513.56
Operating Cash Outflows for Operating Leases ($M)($M)
6.105.905.604.904.804.504.304.204.104.1043.20
Weighted-Average Remaining Lease Term — Operating Leases (years)(năm)
7.07.26.96.97.17.47.88.06.36.56.76.9
Weighted-Average Discount Rate — Operating Leases (%)(%)
6.6%6.5%6.8%7.0%7.1%7.1%7.2%7.2%6.8%6.8%6.8%6.7%
Total Undiscounted Future Operating Lease Payments ($M)($M)7
2012041701511491491411449295.799.5101
Lease Maturity: Next Fiscal Year / Year 1 ($M)($M)
25.124.624.322.221.120.317.517.417.217.016.616.0
Lease Maturity: Year 2 ($M)($M)
28.027.524.221.620.519.717.817.717.517.316.916.4
Lease Maturity: Year 3 ($M)($M)
28.127.624.121.520.419.817.11714.314.317.316.7
Lease Maturity: Year 4 ($M)($M)
28.628.022.819.818.818.317.417.36.676.6314.213.7
Lease Maturity: Year 5 ($M)($M)
23.117.36.59
Lease Maturity: Thereafter / After Year 5 ($M)($M)
51.053.327.9
Less: Imputed Lease Interest ($M)($M)
42.744.735.532.232.834.233.835.718.419.620.821.5
Unvested Restricted Stock Units (RSUs & PSUs) Outstanding (thousand shares)4
7,321.007,949.008,323.008,893.009,498.009,974.0011.0010,856.0011,338.0011,901.009.009,440.00
Unvested RSUs Weighted-Average Grant-Date Fair Value ($/sh)($)
13412810094.9290.8986.7561.2857.9156.5956.1649.5050.28
RSUs & Performance Units Granted in Period (thousand shares)
168.002,457.00-3,276.00271.00288.002,721.00-5,038.00257.00178.004,608.00-5,722.00262.00
RSUs & Performance Units Vested in Period (thousand shares)
701.002,686.00-4,632.00711.00690.003,236.00-2,964.00525.00582.001,861.00-2,361.00340.00
RSUs & Performance Units Forfeited/Canceled in Period (thousand shares)
95.00145.00-342.00165.0074.00104.00-466.00214.00159.0094.00-759.00140.00
Stock Options Outstanding (thousand shares)2
3,132.003,242.003,591.003,739.003,804.003,822.003,875.004,176.004,423.004,709.005,501.005,532.00
Stock Options Outstanding — Weighted-Average Exercise Price ($/sh)($)
29.2828.7727.0330.5530.5430.4730.2228.6727.4526.2523.6523.57
Stock Options Outstanding — Aggregate Intrinsic Value ($M)($M)
725496231143
Performance-Based Stock Award Compensation Expense ($M)($M)2
24.521.975.125.529.818.723.37448.520.713.723
Unrecognized Stock-Based Compensation Expense — RSUs & Options ($M)($M)
637509332368
Weighted-Average Remaining Recognition Period for Unrecognized SBC (years)(năm)
1.61.62.42.5
Antidilutive Securities Excluded from Diluted EPS: RSUs & Performance Awards (thousand shares)2
7,321.007,949.008,323.008,893.009,498.009,974.0010,593.0010,856.0011,338.0011,901.009,248.009,440.00
Antidilutive Securities Excluded from Diluted EPS: Stock Options (thousand shares)
3,132.003,242.003,591.003,739.003,804.003,822.003,875.004,176.004,423.004,709.005,501.005,532.00
Antidilutive Securities Excluded from Diluted EPS: ESPP Shares (thousand shares)
29.0079.0034.0088.0039.0098.0040.0093.0041.00221.0088.00188.00
Census QSS Quarterly Revenue: U.S. Medical & Diagnostic Laboratories — NAICS 6215 ($M)($M)5
20,52819,56919,99719,67719,71818,72219,10418,89318,48317,96317,94317,348
Census QSS Quarterly Revenue: Ambulatory Health Care Services — NAICS 621 ($M)($M)
414,886395,174407,176398,164389,960373,423380,950366,854362,208347,178347,128331,113
Census QSS Quarterly Revenue: Outpatient Care Centers — NAICS 6214 ($M)($M)
45,10844,02245,30042,79741,83240,03040,60237,89737,22736,08737,03033,974
Census QSS Quarterly Revenue: Hospitals — NAICS 622 ($M)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,26441,441
BEA Personal Consumption Expenditures: Health Care Services — SAAR ($B)
3,790.303,699.903,667.003,614.903,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
BEA Real PCE Quantity Index: Health Care Services (2017=100)
135.90133.62133.63132.73130.45129.02127.88126.71124.83123.75121.53119.23
Exact Sciences Corp. (EXAS) — GAAP Revenue ($M)15
Guardant Health, Inc. (GH) — GAAP Revenue ($M)($M)
335302281265232203202191177168155143
Guardant Health, Inc. (GH) — GAAP Operating Income / Loss ($M)($M)
-129-121-121-99-106-111-126-117-101-100-198-114
Myriad Genetics, Inc. (MYGN) — GAAP Revenue ($M)($M)
191200210206213196211213212202197192
Myriad Genetics, Inc. (MYGN) — GAAP Operating Income / Loss ($M)($M)
-39-31-6-23-329-29-39-20-36-28-31-60
Veracyte, Inc. (VCYT) — GAAP Revenue ($M)($M)
150139141132130114119116114979890
Veracyte, Inc. (VCYT) — GAAP Operating Income / Loss ($M)($M)
23233723-534125-5-36-32
CareDx, Inc. (CDNA) — GAAP Revenue ($M)($M)
1321181081008785878392726667
CareDx, Inc. (CDNA) — GAAP Operating Income / Loss ($M)($M)
1131-60-11-1384-14-7-23-123-29
NeoGenomics, Inc. (NEO) — GAAP Operating Income / Loss ($M)($M)
-10-18-13-27-48-28-18-21-22-31-19-24
Illumina, Inc. (ILMN) — Next-Gen Sequencing Supplier GAAP Revenue ($M)($M)
1,1591,0911,1591,0841,0591,0411,1041,0801,1121,0761,1191,176
Illumina, Inc. (ILMN) — GAAP Operating Income / Loss ($M)($M)
245209201227214164175741-1,637-111-754-88
Quest Diagnostics Inc. (DGX) — Clinical Lab Peer GAAP Revenue ($M)($M)
3,0432,8952,8062,8162,7612,6522,6212,4882,3972,3662,2882,295
Quest Diagnostics Inc. (DGX) — GAAP Operating Income ($M)($M)
459399386386438346361330355300267342
Labcorp Holdings Inc. (LH) — Clinical Lab Peer GAAP Revenue ($M)($M)
3,7313,5383,5163,5643,5273,3453,3293,2823,2213,1773,0333,057
Labcorp Holdings Inc. (LH) — GAAP Operating Income ($M)($M)
452381268397394326216254295321-123252
Revenue by Offering Type — Product vs. Licensing and Other ($M, DB)($M)2
753697666592547502476440413368311268
Cost of Product Revenues ($M)($M)
267245219207200185176168170159151147
Cost of Licensing and Other Revenues ($M)($M)
10.600.800.500.500.500.500.400.300.300.200.30
Income Statement — Total Consolidated Revenue ($M, DB)($M)12
753697666592547502476440413368311268
Research and development expense ($M)($M)
22821117517314612913096.989.188.68377.2
Selling, general and administrative expense ($M)($M)
327328291309311267235214198194161155
Total operating costs and expenses ($M)($M)
829790688690657581541479457442396379
Operating income / loss ($M)($M)
-75.8-93.5-22.8-97.6-110-79.2-64.7-39.3-43.9-74.3-84.5-111
Interest expense ($M)($M)
0.890.890.991.041.0311.293.143.133.123.153.25
Income / loss before income taxes ($M)($M)
-67.2-84.8-13.3-87.3-101-66.8-55.1-30.9-36.6-67.2-77.8-109
Income tax expense / benefit ($M)($M)
-0.260.28-60.60.210.270.17-1.350.730.890.430.190.20
Net income / loss ($M)($M)
-67-85.147.3-87.5-101-66.9-53.8-31.6-37.5-67.6-78-109
Net income / loss per share — Basic ($/sh)($)
-0.47-0.60-0.64-0.74-0.50-0.26-0.30-0.56-0.95
Net income / loss per share — Diluted ($/sh)($)
-0.47-0.60-0.64-0.74-0.50-0.26-0.30-0.56-0.95
Weighted-average basic shares outstanding (M)
143.30141.50137.20136.40134.80123.80122.90120.80115.20
Weighted-average diluted shares outstanding (M)
143.30141.50137.20136.40134.80123.80122.90120.80115.20
Balance Sheet — Total Assets ($M, DB)($M)18
2,6582,6142,3981,8221,7571,7321,6611,5911,5171,4681,4421,447
Cash and cash equivalents ($M)($M)
1,0921,0881,0761,0411,000974946893797814642669
Accounts receivable, net ($M)($M)
422418297286309318314307336289278255
Inventory ($M)($M)
80.370.768.464.654.350.444.748.7414340.842.1
Prepaid expenses and other current assets ($M)($M)
65.175.655.853.952.156.248.644.637.846.760.533.5
Total current assets ($M)($M)
1,6591,6521,4971,4471,4321,4161,3761,3231,3021,2611,2591,267
Property and equipment, net ($M)($M)
318269241207189181162142133126111105
Operating lease right-of-use assets ($M)($M)
1301341099795.194.686.187.952.654.656.558.2
Goodwill ($M)($M)
141141141
Intangible assets, net ($M)($M)
36036737410.9
Other long-term assets ($M)($M)
505136.970.741.140.925.838.429.326.415.416.2
Accounts payable ($M)($M)
75.262.433.246.536.939.234.927.833.1261521.3
Accrued expenses and other current liabilities ($M)($M)
229213189216191178147126141142149134
Deferred revenue, current ($M)($M)
40.636.924.921.821.620.619.817.918.417.716.615
Total current liabilities ($M)($M)
553558441442385366344301315306307290
Total liabilities ($M)($M)
836840686569511493465712681674676662
Additional paid-in capital ($M)($M)
4,7504,6354,4894,0763,9823,8753,7643,3933,3203,2413,1463,089
Accumulated deficit / retained earnings ($M)($M)
-2,928-2,861-2,776-2,823-2,736-2,635-2,568-2,514-2,483-2,445-2,377-2,299
Total stockholders' equity ($M)($M)
1,8221,7741,7121,2521,2461,2401,195879837794765785
Cash Flow Statement — Operating Cash Flow ($M, DB)($M)6
54.840.273.959.437.644.552.951.8427-57.6-29.7
Stock-based compensation ($M)($M)
10395.192.690.693.477.871.970.667.464.449.457.6
Depreciation and amortization ($M)($M)
15.514.512.410.39.909.207.808.207.907.106.907
Purchases of property and equipment — CapEx ($M)($M)
63.422.136.122.425.921.818.116.311.720.310.19
Net cash used in investing activities ($M)($M)
-63.4-32.1-71.6-19.9-23.9-16.8-11.142.5-32.113824.181.3
Net cash provided by financing activities ($M)($M)
12.23.8032.41.9012.60.50111.70116.506.80236
Cash paid for interest ($M)($M)
0.890.890.991.041.0311.111.194.411.184.441.31

14 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & single reportable segment: Natera, Inc. (NASDAQ: NTRA, CIK 0001604821) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Natera manages its cell-free DNA (cfDNA) molecular diagnostics business as a single reportable operating segment across three primary clinical franchises: Women's Health (Panorama NIPT, Horizon Carrier Screening, Vistara, Spectrum, Empower, Anora), Oncology (Signatera personalized ctDNA minimal residual disease [MRD] test and Altera comprehensive genomic profiling), and Organ Health (Prospera transplant rejection assessment and Renasight kidney gene panel).
  • Core operational & diagnostic volume KPIs (Groups 1–2) cover: (1) Total Tests Processed (985,600 in Q2 2026 / 3,522,000 in FY2025 across 35 quarters 2017Q1–2026Q2 and 10 years FY2015–FY2025), Tests Accessioned in Natera's CLIA Laboratories (966,600 in Q2 2026 / 3,453,100 in FY2025), Total Tests Reported (3,290,000 in FY2025), Total Oncology Tests Processed (242,800 in Q2 2026 / 814,200 in FY2025), Clinical MRD Oncology Tests Processed (228.5 thousand in Q2 2026 / 769,700 exact clinical tests in FY2025), and Signatera Realized ASP (~$1,300/test in Q2 2026 up from ~$1,165/test in Q2 2025); and (2) Revenue Disaggregated by Payer Type across 38 quarters (Insurance Carriers $705.09M [93.7%], Laboratory Partners $37.74M [5.0%], Patients $9.92M [1.3%] in Q2 2026), Legacy Product Revenue Disaggregation (Panorama NIPT, Horizon HCS, Other Genetic Tests, Constellation, Other Licensing through 2020Q1), Sales Channel Mix (97% U.S. Direct Sales Force in FY2025), Prior-Period Cash Collection Revenue True-Ups ($52.3M or $0.36/sh diluted EPS impact in Q2 2026; $161.3M or $1.18/sh in FY2025), and GAAP Gross Profit ($498.4M / 66.2% gross margin in Q2 2026; $1,481.2M / 64.1% in FY2025).
  • Contract liabilities, purchase obligations, laboratory infrastructure & governance (Groups 3–6) cover: (3) Contract Liabilities ($64.25M total at Q2 2026 across $31.73M current and $32.52M noncurrent) with complete quarterly roll-forward (additions, revenue recognized from beginning balance, and same-period deferrals) and BGI Genomics / Foundation Medicine / Qiagen collaboration balances; (4) Unconditional Purchase Obligations ($189.20M total at Q2 2026 across $87.90M inventory & sequencing consumables, $39.56M other material suppliers, $36.13M application & IT services, $17.87M laboratory instruments, $6.47M cloud computing, and $1.27M clinical trial samples); (5) CLIA Laboratory Facilities (520,256 sq ft total in FY2025 across San Carlos, CA 136,000 sq ft, Austin, TX 225,847 sq ft, and South San Francisco, CA 88,974 sq ft), Property & Equipment ($256.83M gross / $143.93M net at Q2 2026 including $147.82M machinery & lab sequencers and $67.74M leasehold improvements), Foresight Diagnostics acquisition contingent consideration liability ($98.06M fair value at Q2 2026), and Operating Lease Maturity Schedule ($93.31M lease liabilities / $126.90M undiscounted payments at Q2 2026); and (6) Equity Awards (5,637K unvested RSUs at $115.65 WAGDFV and 3,591K options at $30.22 WAEP), Antidilutive Securities, and DEF 14A CEO/NEO Pay-Versus-Performance & CEO Pay Ratio (111x in FY2025).
  • Workforce, safety, environmental sustainability & benchmarks (Groups 7–9) cover: (7) Global Workforce (5,021 total / 4,768 full-time employees at FY2025; 64.2% female, 58.6% U.S. racial/ethnic minority), OSHA Laboratory Safety (6 recordable injuries, 0.144 TRIR, 0.048 LTIR, 0.048 DART rate in FY2025), and Volunteer Hours (3,816 hours in FY2025); (8) Rebaselined GHG Inventory (227,208.94 tCO2e Total Scope 1–3 emissions and 0.066 tCO2e/test intensity in FY2025 across Scope 1 848.72 tCO2e, Scope 2 Market-Based 3,377.37 tCO2e / Location-Based 6,425.16 tCO2e, and Scope 3 222,982.85 tCO2e across all 7 categories, plus grid/renewable electricity, non-hazardous & biohazardous laboratory waste streams [0.168 lbs/test], and municipal water usage [4.08 gal/test]); and (9) 23 Federal Reserve FRED healthcare/laboratory macro series, 17 SEC XBRL peer series (EXAS, GH, MYGN, VCYT, CDNA, NEO, ILMN, DGX, LH), and Natera's DB Financial Statements & Product/Geographic Segments.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; approximate bound disclosures such as '>60% market share' or '>1,000,000 cumulative patients' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-11-02.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Diagnostic Test Volumes, Oncology MRD Adoption & Signatera ASP

Contract Liabilities (Deferred Revenue Roll-Forward) & Strategic Partnership RPO

Unconditional Purchase Commitments & Sequencing / Cloud Supply Obligations

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Natera

See a number that looks wrong?